• News
  • BioTech

Mirati Therapeutics receives orphan drug designation for mocetinostat

Mirati Therapeutics Inc. (Nasdaq: MRTX) has announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted orphan drug designation by the U.S. Food & Drug Administration as a treatment for myelodysplastic syndrome (MDS).

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!